News Snapshot:
Beijing, November 15: China is set to approve the country's first monoclonal antibody combination therapy against Covid-19 by December, according to media reports. Monoclonal antibodies are proteins designed to attach to a specific target, in this case the spike protein of SARS-CoV-2, which the virus uses to enter human cells. The combination therapy is co-developed by Tsinghua University, the Third People's Hospital of Shenzhen and Brii Biosciences headquartered in China and the US, Global Times reported. It is also likely to be the first to receive emergency use authorisation in developed countries such as the US. "Human bodies produce a...
